ppar-delta could stellar differenti mechan add nash portfolio
invest summari reiter overweight pt think
limit read-through clinic ow young
selonsertib failur cbay seladepar mechan action also think
remain commit nash/liv diseas think compani could
acquir asset current mechan action like ppar-
see read-through setback ppar-delta agonist seladepar
surpris gilead meet primari endpoint
studi nash patient cirrhosi given rel limit
phase data asset note seladepar show compel activ
pbc somewhat relat liver diseas nash think biolog
ppar delta unlik ppar-alpha primari target elafibranor
potenti anti-fibrot properti addit known metabol benefit
lipid see potenti seladelpar nash studi
also think setback could increas chanc
 nash seladepar select ppar-delta clinic
develop mechan action current
analyst note compani remain commit nash
commerci space although selonsertib studi read yet think
confid like much lower result trial fail
think like look add asset nash portfolio time
could also earli data seladepar nash base current valuat
could reason consider note
cash
continu see compel risk reward seladelpar proof-
of-concept nash data see upsid vs downsid
npv pbc-alon roughli downsid
current level think longer term provid key piec support
upsid share success pbc nash npv
sh upsid success pbc base case success
nash dcf upsid think seladelpar opportun pbc
underappreci model unadjust sale
recent deep dive seladelpar ppar-delta anoth
nash readout reiter overweight increas pt
disclosur section may found page
valuat base dcf analysi appli discount rate termin
growth rate line peer similar size develop stage probabl adjust
revenu estim seladelpar
lack efficaci pbc nash
signific capit need potenti dilut fund phase develop program
 greater-than-expect competit pbc and/or nash highli
competit space evolv commerci bar efficaci
 although unlik key risk clinic asset unexpect safeti signal could
cymabay clinic stage biotechnolog compani focus develop therapeut liver diseas lead asset
seladelpar select ppar- delta peroxisom proliferator-activ receptor develop pbc primari biliari ciholang
nash non-alcohol steatohepat
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
lead co-manag cantor fitzgerald and/or affili act lead co-manag public offer equiti and/or debt secur cymabay
therapeut inc within last month
invest bank last month cantor fitzgerald and/or affili receiv compens invest bank servic last month
inc
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
cantor fitzgerald and/or affili market maker gilead scienc inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
materi approv distribut unit kingdom cantor fitzgerald europ cfe cfe authoris regul
conduct author fca believ inform materi upon inform base accur except
oblig rule fca guarante accuraci materi intend use elig counterparti profession
client fall within articl servic market act promot order gener invest
public none invest invest servic mention describ herein avail person particular
avail retail client defin rule fca
disclosur canadian institut investor
research report prepar analyst cantor fitzgerald co cantor fitzgerald canada corpor result report
prepar subject canadian disclosur requir cantor fitzgerald canada may distribut research report prepar affili
financi instrument discuss report may suitabl investor investor must make invest decis base
specif invest object past perform taken indic guarante futur perform price valu
incom financi instrument featur report rise well fall affect chang econom financi polit
factor financi instrument denomin currenc investor currenc chang exchang rate may advers affect price
valu incom deriv financi instrument investor effect assum currenc risk addit investor secur
adr whose valu affect currenc home market underli secur effect assum currenc risk
rate price target histori inc
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
distribut ratings/invest bank servic ib
addit inform avail request copyright cantor fitzgerald
head healthcar research
